E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/15/2006 in the Prospect News Biotech Daily.

Merrill reiterates Speedel at buy

Speedel Holdings was reiterated by Merrill Lynch analyst Erica Whittaker at a buy on news of the company's third-quarter results, including operating expenses that were more than 20% below the analyst's forecast and leading to a lower-than-expected loss of CHF 16.3 million. The company's cash balance at the end of September was CHF 145 million, with 2006 cash burn now expected in the range of CHF 70 million to CHF 75 million, from CHF 80 million. Merrill is forecasting CHF 82 million. Shares of the Basel, Switzerland, pharmaceutical company were up CHF 0.70, or 0.35%, at CHF 196.60. (Swiss: SPPN)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.